Clinical trials: Corneal Endothelial Cell
- Condition Corneal Endothelial Cell
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Ocular Inflammation and Pain After Cataract Surgery
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04810962
- Testing
- APP13007, 0.05%
- Where
- 31 sites in United States
- Volunteers
- 370 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Corneal Endothelial Cell Loss
Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality
The primary objective of this clinical study is to collect clinical data to support an FDA 510(k) submission for the Nidek CEM-530 Center point method and Corner point method.
- Trial name
- NCT02276638
- Testing
- Specular Microscope Nidek CEM-530, Specular Microscope Konan CELLCHEK XL
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Nidek Co. LTD.
Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Prospective, multicenter, randomized, masked, vehicle-controlled, dose-escalation study
- Conditions
- Corneal Endothelial Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Endothelial Dysfunction
- Trial name
- INTREPID (NCT04520321)
- Testing
- TTHX1114(NM141)
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- Trefoil Therapeutics, Inc.
Corneal Endothelial Cell Loss, Ocular Pain
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Trial name
- NCT02128113
- Testing
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Where
- 15 sites in United States
- Volunteers
- 307 people
- Sponsor
- Biogen
Dry Eye Disease, Endothelial Cell
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)
- Trial name
- NCT06329661
- Testing
- Cyclosporine ophthalmic solution, 0.1%, Saline solution, 0.6%
- Where
- 6 sites in United States
- Volunteers
- 204 people
- Sponsor
- Novaliq GmbH